Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 8/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | POLR1A | O95602 | 3/20 | 0.43 |
| ▸ | ECE1 | P42892 | 1/20 | 0.43 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.43 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 4/20 | 0.42 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL634157 | 0.90 | RAD52 (0.44) | POLR1AECE1MUS81AOX1RAD52 | |
| SCHEMBL634304 | 0.90 | POLR1A (0.47) | POLR1AECE1MUS81AOX1RAD52 | |
| SCHEMBL634104 | 0.89 | POLR1A (0.50) | POLR1AECE1MUS81AOX1RAD52 | |
| SCHEMBL634412 | 0.86 | POLR1A (0.48) | POLR1AECE1MUS81AOX1RAD52 | |
| SCHEMBL635572 | 0.86 | RAD52 (0.48) | POLR1AECE1MUS81AOX1RAD52 | |
| SCHEMBL634698 | 0.86 | POLR1A (0.45) | POLR1AECE1MUS81AOX1RAD52 | |
| SCHEMBL635605 | 0.85 | TNF (0.52) | TNFCNR1 | |
| SCHEMBL634268 | 0.84 | RAD52 (0.43) | POLR1AECE1MUS81AOX1RAD52 | |
| SCHEMBL31125271 | 0.84 | RAD52 (0.48) | POLR1AECE1MUS81AOX1RAD52 | |
| SCHEMBL30122363 | 0.82 | RAD52 (0.49) | POLR1AECE1MUS81AOX1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1507778-B1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | UNIV TROBE (AU) | 2012-02-22 | — | — | EP | disclosed |
| US-20090156630-A1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | BAGULEY BRUCE CHARLES | 2009-06-18 | — | — | US | disclosed |
| US-7504507-B2 | Anti-tumour polycyclic carboxamides | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-03-17 | — | — | US | disclosed |
| US-20050245561-A1 | Anti-tumour polycyclic carboxamides | AUCKLAND UNISERVICES LIMITED (NZ) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156630-A1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | MKI67, MCL1, CCNI | TNF 1504/4885CNR1 295/4885POLR1A 833/4885 |
| US-20050245561-A1 | Anti-tumour polycyclic carboxamides | MKI67, MCL1, CCNI | TNF 1402/4885CNR1 350/4885POLR1A 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.